Hologic Inc.
Hologic Announces Strong Financial Results and Share Repurchase Program
Summary
Hologic, Inc. announced its financial results for the fourth quarter and fiscal year ended September 28, 2024. The company reported a revenue of $987.9 million, an increase of 4.5% for the quarter and 4.2% in constant currency. Key highlights include GAAP Diluted EPS of $0.76 and Non-GAAP Diluted EPS of $1.01. Hologic also completed two significant acquisitions: Endomagnetics Ltd for approximately $310 million and Gynesonics, Inc. for approximately $350 million. Additionally, the company repurchased 11.2 million shares of its common stock for $808 million in fiscal 2024 and plans to enter into an accelerated share repurchase (ASR) agreement for $250 million in Q1 2025.
Profitelligence Alerts
Get alerts for HOLX
Be first to know when Hologic Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Hologic Inc.
Hologic Inc. is a leading global medical technology company focused on improving women's health and well-being. Its primary function is to develop, manufacture, and supply diagnostic products, medical imaging systems, and surgical products, which play crucial roles in the prevention and treatment of diseases. Hologic's key sectors include breast health, diagnostics, gynecological surgical, and skeletal health solutions. It is renowned for innovative technologies such as 3D mammography or tomosynthesis, which are significant advancements in breast cancer detection. With a commitment to enhancing healthcare quality and efficiency, Hologic operates across a diverse range of healthcare settings, from hospitals and clinics to laboratories and research facilities. Headquartered in Marlborough, Massachusetts, Hologic has established itself as a pivotal player in women's health diagnostics, contributing to its substantial market presence and influence in the global healthcare sector.
Official SEC Documents
Advertisement